Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02345252 |
|---|---|
| Brief Title: | Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) |
| First Submitted : | January 19, 2015 |
| First Submitted that Met QC Criteria : | January 19, 2015 |
| First Posted : | January 26, 2015 (Estimate) |
| Results First Submitted : | September 20, 2017 |
| Results First Submitted that Met QC Criteria : | November 7, 2017 |
| Results First Posted : | December 8, 2017 |
| Certification/Extension First Submitted : | February 14, 2017 |
| Certification/Extension First Submitted that Met QC Criteria : | February 14, 2017 |
| Certification/Extension First Posted : | February 16, 2017 |
| Last Update Submitted that Met QC Criteria : | December 16, 2019 |
| Last Update Posted : | January 2, 2020 |